TABLE 1.
Baseline characteristic of patients in the development and validation cohort.
| level | Development cohort(n = 426) | Validation cohort (n = 328) | |||||
|---|---|---|---|---|---|---|---|
| Low Risk | High Risk | P | Low Risk | High Risk | P | ||
| n | 268 | 158 | 200 | 182 | |||
| Age (mean (SD)) | 58.732 (12.676) | 59.816 (15.649) | 0.4878 | 56.799 (13.099) | 57.134 (13.191) | 0.833 | |
| Sex (%) | F | 116 (43.28) | 57 (36.08) | 0.1735 | 92 (46.00) | 68 (37.36) | 0.1085 |
| M | 152 (56.72) | 101 (63.92) | 108 (54.00) | 114 (62.64) | |||
| TNM stage (%) | I | 28 (10.45) | 7 (4.43) | <0.0001 | 38 (19.19) | 35 (19.34) | 0.0026 |
| II | 126 (47.01) | 29 (18.35) | 69 (34.85) | 42 (23.20) | |||
| III | 99 (36.94) | 53 (33.54) | 63 (31.82) | 52 (28.73) | |||
| IV | 15 (5.60) | 69 (43.67) | 28 (14.14) | 52 (28.73) | |||
| T stage (%) | T1 | 14 (5.22) | 5 (3.18) | 0.0001 | 9 (4.55) | 8 (4.42) | 0.6512 |
| T2 | 23 (8.58) | 4 (2.55) | 35 (17.68) | 29 (16.02) | |||
| T3 | 208 (77.61) | 112 (71.34) | 133 (67.17) | 117 (64.64) | |||
| T4 | 23 (8.58) | 36 (22.93) | 21 (10.61) | 27 (14.92) | |||
| N stage (%) | N0 | 157 (58.80) | 51 (32.90) | <0.0001 | 118 (59.00) | 84 (46.15) | 0.0175 |
| N1 | 84 (31.46) | 65 (41.94) | 58 (29.00) | 60 (32.97) | |||
| N2 | 26 (9.74) | 39 (25.16) | 24 (12.00) | 38 (20.88) | |||
| M stage (%) | M0 | 253 (94.40) | 89 (56.33) | <0.0001 | 172 (88.21) | 130 (78.31) | 0.0168 |
| M1 | 15 (5.60) | 69 (43.67) | 23 (11.79) | 36 (21.69) | |||
| Differentiation grade (%) | Low | 57 (30.81) | 29 (26.36) | 0.0256 | 45 (36.00) | 29 (25.44) | 0.181 |
| Moderate | 117 (63.24) | 64 (58.18) | 76 (60.80) | 79 (69.30) | |||
| High | 11 (5.95) | 17 (15.45) | 4 (3.20) | 6 (5.26) | |||
| Chemotherapy Adjuvant (%) | No | 68 (32.69) | 32 (32.65) | 1 | 108 (56.84) | 102 (61.82) | 0.3992 |
| Yes | 140 (67.31) | 66 (67.35) | 82 (43.16) | 63 (38.18) | |||